$10.26
2.60% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US2300311063
Symbol
CGEM

Cullinan Oncology Inc Stock price

$10.26
-2.67 20.65% 1M
+2.42 30.87% 6M
-1.92 15.76% YTD
-2.01 16.38% 1Y
+0.02 0.20% 3Y
-10.74 51.14% 5Y
-10.74 51.14% 10Y
-10.74 51.14% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.26 2.60%
ISIN
US2300311063
Symbol
CGEM
Industry

Key metrics

Basic
Market capitalization
$606.1m
Enterprise Value
$273.5m
Net debt
positive
Cash
$332.6m
Shares outstanding
59.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
94.9%
Return on Equity
-28.4%
ROCE
-53.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-241.1m | $-231.4m
EBIT
$-241.4m | $-247.3m
Net Income
$-216.8m | $-212.7m
Free Cash Flow
$-174.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-28.9% | -17.7%
EBIT
-28.9% | -25.6%
Net Income
-51.0% | -27.1%
Free Cash Flow
-37.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.7
FCF per Share
$-3.0
Short interest
13.5%
Employees
111
Rev per Employee
$0.0
Show more

Is Cullinan Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Cullinan Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Cullinan Oncology Inc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Cullinan Oncology Inc forecast:

Buy
94%
Hold
6%

Financial data from Cullinan Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
13% 13%
-
- Research and Development Expense 185 185
35% 35%
-
-241 -241
29% 29%
-
- Depreciation and Amortization 0.31 0.31
0% 0%
-
EBIT (Operating Income) EBIT -241 -241
29% 29%
-
Net Profit -217 -217
51% 51%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cullinan Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cullinan Oncology Inc Stock News

Neutral
Seeking Alpha
16 days ago
Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript
Neutral
GlobeNewsWire
17 days ago
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently gr...
Neutral
GlobeNewsWire
24 days ago
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune di...
More Cullinan Oncology Inc News

Company Profile

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Nadim Ahmed
Employees 111
Founded 2016
Website cullinantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today